Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
OwnerEdward L. Tobinickinventor
Life of this patent
Estimating the term…
Abstract
Interleukin (IL) antagonists are provided for the treatment in humans of neurological disorders, trauma, injuries or compression; neurodegenerative disorders including Alzheimer's Disease; demyelinating neurological disorders including multiple sclerosis; retinal disorders; and muscular disorders. The IL antagonists are used to treat these disorders by inhibiting the action of IL in the human body. The administration of these IL antagonists is performed by intrathecal administration; intracerebroventricular administration; intranasal administration; by inhalation; or by alternative routes of administration.
Claims30
A method for inhibiting the action of interleukin (IL) for treating neurological conditions in a human by administering an IL Blocker for reducing the inflammation of neuronal tissue or the neuromuscular junction of said human, or for modulating the immune response affecting neuronal tissue or the neuromuscular junction of said human, comprising the step of:
- a) administering a therapeutically effective dosage level to said human of said IL Blocker for reducing the inflammation of neuronal tissue or the neuromuscular junction of said human, or for modulating the immune response affecting neuronal tissue or the neuromuscular junction of said human;
- and
- b) administering said IL Blocker into the cerebrospinal fluid (CSF) of said human.
Dependencies are inferred from the claim text.